Scribd Logo
Upload

Welcome to Scribd!

  • Novartis Swot and Pestel - S&P

    Uploaded by

    rudy_tanaga
    259 views6 pages
    Novartis Swot and Pestel

    Original Title

    Novartis Swot and Pestel - s&p

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    Novartis Swot and Pestel

    Copyright:

    © All Rights Reserved
    Download as PDF or read online from Scribd
    Flag for inappropriate content
    259 views6 pages

    Novartis Swot and Pestel - S&P

    Uploaded by

    rudy_tanaga
    Novartis Swot and Pestel

    Copyright:

    © All Rights Reserved
    Download as PDF or read online from Scribd
    Flag for inappropriate content
    of 6
    911412019 Novartis International SWOT & PESTLE Analysis - SWOT & PESTLE.com & (emaitsupport@swotandpestle.com) £ [httpsy/www facebook com/swotendpestie) ¥ (https//twittercon/SWOT_PESTLE) in (hitps://wwuulinkedin.com/company-beta/13273899/2pathwildcard=13273899) Ge (https//olus.google-com/110900927263289089557) Soares aura. Login https//Awwwswotandpestle.com/login) SignUp (https:/jwww-swotandpestle.conysignup) Find comprehensive SWOT and PESTLE research reports across industries globally Search by organization, industry/sector, country/region ‘Search © Holistic Analysis ? Customized Solutions © Top Quality , 7 onDER A CUSTOM REPORT Novartis International SWOT & {bttps:/wuoswotandpestlecomysoltions) PESTLE Analysis ‘Are yn ooking fora repre nt covered on our (https://www.swotandpestle.com/novalHte: F tros/iménternationalf) WD (heeps//twittelosgBMBs3pesEhAec 2018 in (tps/imnu MEANY BREIL 2 Nowartisdntecnationa, © cretosymnn BHSIRSES SCbOE Bharmaceuticals Operating Geography : switzerland, Global About Novartis International : Novartis International AG, 2 Swiss multinational pharmaceutical Other Companies in company based in Base, Switzerland, it has a history going back more Pharma Europe than 150 years. Novartis was Formed after joining the pharmaceutical Novo Nordisk SWOT & PESTLE Analysis (https//wwwswotandpestle.com/novor Ciba-Geigy merged with Sandoz. Sandoz division offers more than 1000 nordisk) ‘and agrochemical businesses of Cibe-Geigy and Sandoz; when in 1996, different types of high quality, afferdable products across various Medtronic SWOT and PESTLE Analysis, (https/mww.swotandpestie.com/medtronic) Sanofi SWOT and PESTLE billion as per Dec 2016. The company has around 123,000 employees Analysis (hetps://mwow.swatandpestle.com/sanofl Merck SWOT and PESTLE Novartis international Revenue: § 48.5 billion - for FY ending Analysis (hteps//wwu.swotandpestie.com/merck) Astrazeneca SWOT & PESTLE Analysis, (nttps://mwuswotandpestle.comfastrazeneca) therapeutic areas and the division is a global leader in generic medicines and biosimilars. Market capitalisation of the company is $172, ‘and their products are available in 155 countries as of 2016, Dec 2016 Competitive Analysis of Novartis International swot PESTLE sions The SWOT analysis for Novartis Internationalis presented below. _(https//Wwww-swotatdpestle:com/category/Pharma) Strengths Weaknesses i ‘Other Companies in Pharma Molina Healthcare SWOT & PESTLE Analysis (httpsy/wwwuswotandpestle.com/molina- heatthcare) pe Tel F hetps/pvwFsBRBEESom/swotandpeste) IF (heeps;/owitersony/swy Novartis International SWOT & PESTLE Analysis - SWOT & PESTLE.com 1. Global Healthcare company | 1.Salesis dectining 2. Research &Development is 2.Ceclining growth in main Focus oF the company’s Established medicines strategy 3. Anthinfectives business is also 3. trong product portfolio declining 4. Growing therapy areas 5. Corporate responsibility Opportunities Theeats, 1. Strong demographic and 1. Competition From generics economic trends 2. Increasing pressure on 2. Rising demand for biosimilars healthcare costs 3. Great potential ofemersing 3, Risk For drug prices 4. Challenges with emerging 4, Growing medical research PEST fay Seaitent markets fin (netes//mwviinkedin.com/company-beta/13273089/rpathiwildcard=13273898) 8 + § ‘SWOT & PESTLE (hetpsynwinstagranQpnvswotandps aw (combined) Sample Freesummary Complete Report Complete Report Report USD 12.53 BUY NOW. with PayPal * By clicking on ‘Buy Now" you agree to accept our “Terms and Conditions, with Debit/Credit card (hutosy/www.swotandpestie.com/termsereat quality, Affordable aricing, ‘andeconcitions)” 4 @ Safe and secure payments, Detailed SWOT Analysis of Novartis International Strengths 1, Global Healthcare company: Novartis, a Switzerland based global healthcare company, Is established more than 150 years ago. They provide healthcare solutions for evolving patients and societies worldwide, Products are available in 155 countries, reaching 1 billion people globally in 2016, About 0.13 million people of 142 nationalities work, The company showed net sales of 48,5 billion USD and market capitalisation of 172 billion USO 2. Research and development is at the Fundamental of the company and centre to the company’s strategy. n the year 2016, with 16 approvals in major markets and 24 applications far marketing approval, they also recelved 5 breakthrough therapy designations From US Food and Drug ep ay AbbVie SWOT & PESTLE Analysis (hteps//wwwswotandpestle.com/abbvie) Mylan SWOTSPESTLE Analysis, (nteps://wwrw.swotandpestle.com/mylan) Boehringer Ingetheim SWOT & PESTLE Analysis (htepsi/wwwswotandpestle.com/boehringer ingetheim) AmerisourceBergen SWOT & PESTLE Analysis (https//wwu.swotandpestle.com/amerisourcebers ew att {httpsy/jwww.swotaidestle’com/category/Pharma) ‘Other Companies in Europe Royal Dutch Shell SWOT & PESTLE Analysis (httpsy//www.swotandpestle.com/royak dutetrshetl) Beiersdorf SWOT & PESTLE Analysis (hteps//www.swotandpestle.com/beiersdorf) Piaggio Group SWOT & PESTLE Analysis (https:/Awwwuswotandpestle.com/piaggio- aroun) Sopra Steria SWOT & PESTLE Analysis (httpsy//www.swotandpestle.com/sopra steria) Auchan Holding SWOT & PESTLE Analysis (https://wwwuswotandpestle.com/auchane holding) {Mew All {httos://www.swotandpestle.com/category/Eurape) pal 911412019 Novartis International SWOT & PESTLE Analysis - SWOT & PESTLE.com ‘Administration (USFDA). In 2016, they filed in the US and EU to market combination of Tafinlar (dabrafenib) and Mekinist (trametinib) as @first- line treatment in tung cancer patients with mutation in BRAF V600. 3, Strong product portfolio t believes to have up to 12 drugs in pipeline to potentially become blockbusters, with therapy areas like oncology, immunology, neurology, eyecare and biosimilars. Alcon, eyecare division launched tivo new surgical technologies like Cypass Micro-Stent and NGENUITY 30 Visualisation systems for treating eye disorders. They also reported postive clinical tral results for two important molecules in neuroscience pipeline: BAF312 (siponimod For secondary progressive multiple sclerosis) and AMG 334 (erenumab for episodic migraine prevention) 4. Growing therapy areas: Novartis progressed beyond target therapies hetos/puwimebsntroto patenpati| clinical data in CTLO19- a personalised cell hero developed in collaboration with university of Pennsylvania in iS tu W (heaps/powitter.com/SWOT_PE in paediatric and young adult patients with B-cell acute lymphoblastic iin (ntpsvimnciahedinremieromeroheba(sARI8d IHERSENWNISRIFEIBBAEBBhercept to F epsom OM epg seas. 5. Corporate responsibility: Through patient access programs 82 million patients were reached, through health education programs 17 milion people were educated. Also, Novartis was recognised in corporate responsibility rankings, where it was ranked 3rd in Access to medicine index. Opportunities 1 Strong demographic and economic trends: Expected rise in the global population by 2630 is 1 billion people adding to 2 sum of 8 billion. Millions of people are migrating from rural areas to cities showing changes in lifestyle and diet that can impact human health. The word's population also continues to age rapidly, with number of people aged {60 or moretto increase by 05 billion to 1.4 billion people by 2030. These patterns are showing increase in chronic diseases like diabetes and heart disease. 2, Rising demand for biosimilars: The global biosimilar market is expected to be US$ 36 billion worth by 2022, according to a report by consultant Netscribes, showing a great potential in biosimilars. For now, Novartis aims to be selling only 8 biosimilars as compared to 3 by March 2020. 3. Great potential of emerging markets: Pharrmemerging markets have potential of an exponential growth, From holding an 18% market share in 2010 to a 31% share in 2020, Growing wealth, massive population, unhealthy lifestyles, increasing life expectancy, more spending on healthcare are some of the merits in the emerging markets. ep ay ADVERTISE WiTH US {tps wun swotandpestiecom/advertse- withus) Reach thousands of Need Strategic Analysis fr this company? Porter's, BCG, Value chain ‘ORDER NOW (httos//mwwswotandpestie.com/solutions) peal 911412019 Novartis International SWOT & PESTLE Analysis - SWOT & PESTLE.com 4, Growing medical research: Innovation in medical research is Fast- tracking, majorly driven by new therapeutic approaches. For e9, the ‘average number of new drugs approved by US FDA from 2012 to 2016 increased extensively 46% compared to the last 5 years, Researches are finding novel ways to treat diseases like gene therapy, RNA based treatments that can intervene in how cells create proteins, Digitalisation in healthcare is also gaining importance. It is also attracting technology firms to pharma industry. 5, Oncology segment: Cancer remains world's No.2 killer even after recent decreases in cancer deaths, In Europe cancer remains the No. 1 killer. A new wave of cancer treatments harnesses the immune system to fight the disease. Breast cancer is the most common cancer in women, leading to 0.5 million deaths worldwide per year. hetpsyjnmuacebook.com/swatandpeste) SWOT & PESTLE FF cepsirwieccomeparesney (combined) in psp ompsribeSHAEROes rot DPLES RE Complete Report Report USD 12.53 © thetps//mmwinstagram.com/swotandpestle) * By clicking on "Buy Now" you agree with PayPal to aceat our"Tems and Conditions, * with Debit/Credit card (httosy/wwn:swotandpestiecom/termscreat quality, Affordable pricing, ‘and-

    You might also like